Stocks Health care TIL
NASDAQ · Health careInstil Bio, Inc. (TIL)
It posted a net loss of $30.3M. At June 30, 2026 it held $5.5M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 13, 2026.
Key facts about Instil Bio, Inc.
- Net worth
- Instil Bio, Inc. has a market value (market cap) of $43.1M at the latest share price, and shareholders' equity of $107.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Revenue and profit
- In fiscal 2021 revenue was $0 (-100.0% year on year), with a net loss of $156.8M.
- Cash flow
- In fiscal 2025 operations used $36.6M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on August 13, 2026 and covers the period to June 30, 2026. Open on SEC EDGAR
- Next earnings report
- Instil Bio, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
What Instil Bio, Inc. does
Instil Bio, Inc. is registered with the SEC under industry code SIC 2836 (Biological Products, (No Diagnostic Substances)). Its shares trade on NASDAQ under the ticker TIL.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$71.4M | -$10.70 | n/a |
| 2024 | n/a | -$74.1M | -$11.39 | -$55.7M |
| 2023 | n/a | -$156.1M | -$24.00 | -$102.7M |
| 2022 | n/a | -$223.2M | -$34.46 | -$264.8M |
| 2021 | $0 | -$156.8M | -$29.65 | -$180M |
| 2021 | $138K | -$37.7M | -$47.28 | -$80.4M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Instil Bio, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- August 13, 2026
- August 13, 2026
- June 11, 2026
- May 15, 2026
- May 15, 2026
- April 24, 2026
- April 24, 2026Additional proxy material DEFA14A
- April 24, 2026Proxy statement DEF 14A
- April 3, 2026Auditor change 8-K
- March 27, 2026
Insider trades
What the people running Instil Bio, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider trades were reported in the last 90 days.
Who owns TIL
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Bronson Crouch13D, may seek influence with 5 related filers | 36.8% | October 22, 2024 |
| BML Investment Partners, L.P.13G, passive | 9.5% | February 9, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 26 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Curative Ventures V LLC | 1,899,004 | 0 |
| BML Capital Management, LLC | 645,600 | 0 |
| Vivo Capital, LLC | 292,743 | 0 |
| Kalehua Capital Management LLC | 199,200 | -123,679 |
| UBS Group AG | 177,423 | +171,045 |
| Vanguard Capital Management LLC | 163,738 | -10,845 |
| Millennium Management LLC | 134,575 | +1,629 |
| BlackRock, Inc. | 55,504 | +3,486 |
| Renaissance Technologies LLC | 50,300 | -8,800 |
| Nomura Asset Management International Inc. | 50,000 | 0 |
| Jacobs Levy Equity Management, Inc | 43,051 | new |
| Geode Capital Management, LLC | 42,234 | -6,777 |
| LPL Financial LLC | 32,075 | +12 |
| Citadel Advisors LLC | 30,639 | -7,923 |
| Vanguard Fiduciary Trust Co | 22,773 | +148 |
| State Street Corp | 17,595 | 0 |
| Americana Partners, LLC | 16,176 | 0 |
| Dimensional Fund Advisors LP | 15,761 | -4,214 |
| Morgan Stanley | 11,934 | -7,887 |
| Vanguard Global Advisers, LLC | 1,470 | 0 |
Insiders
Questions about TIL
What does Instil Bio, Inc. do?
Instil Bio, Inc. is a company in the Health care sector, listed on NASDAQ as TIL. Its shares trade on NASDAQ under the ticker TIL.
What is Instil Bio, Inc.'s net worth?
Instil Bio, Inc. has a market value (market cap) of $43.1M at the latest share price, and shareholders' equity of $107.4M on its balance sheet at June 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Instil Bio, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $30.3M.
When did Instil Bio, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 13, 2026. It covers the period to June 30, 2026.
When is Instil Bio, Inc.'s next earnings report?
Instil Bio, Inc.'s next report is expected around November 12, 2026. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare TIL with
Follow TIL
Get an email when Instil Bio, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Instil Bio, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.